On December 8, 2020, Aifred Health, a Montreal-based digital healthcare company, announced the closing of a $4 million seed financing. This transaction will help to fund the North American regulatory approval clinical trial designed to test the safety and effectiveness of Aifred's artificial intelligence technology to recommend personalized therapeutic treatment choice for patients suffering from clinical depression.
The $4 million raise was co-led by MEDTEQ+ and BDC Capital, with additional support from the Desjardins Group, Highline Beta and other private and institutional investors including follow-on investments from most of the investors in the Company's 2019 pre-seed financing.
A Fasken team comprised of Constantinos Ragas and Jonathan Raizenne advised Aifred Health in connection with this significant financing.
Jurisdiction
- Québec
